© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 23, 1757-1763,
December 4, 2002
© 2002 Oxford University Press
ARTICLE |
Discrete Alterations in the BZLF1 Promoter in Tumor and Non-Tumor-Associated Epstein-Barr Virus
Affiliations of authors: M. I. Gutiérrez, M. M. Ibrahim, King Fahad National Centre for Children’s Cancer and Research (KFNCCC&R), King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; J. K. Dale, S. E. Straus, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; T. C. Greiner, Department of Pathology, University of Nebraska, Omaha; K. Bhatia, KFNCCC&R, King Faisal Specialist Hospital and Research Centre, and Department of Pathology, University of Nebraska.
Correspondence to: Kishor Bhatia, Ph.D., P.O. Box 3354, MBC 98-16, Riyadh, 11211 Saudi Arabia (e-mail: Kishor_Bhatia{at}kfshrc.edu.sa).
Background: Although the Epstein-Barr virus (EBV) is associated with malignant and nonmalignant diseases, its lytic replication is predominately associated with nonmalignant diseases such as acute infectious mononucleosis (IM) or chronic active EBV infection. Lytic replication is also associated with type B EBV more than with type A EBV. Sustained lytic replication, however, is not compatible with tumor growth. We investigated whether control of an EBV lytic regulatory gene, BZLF1, differed in these diseases. Methods: Polymerase chain reaction–single-strand conformation polymorphism (PCR–SSCP) and direct DNA sequence analyses were used to characterize the promoter sequence of BZLF1 (Zp) in 52 tumors (34 non-Hodgkin’s lymphomas, 13 post-transplant lymphoproliferative disease samples, and five nasopharyngeal carcinomas), and in peripheral blood lymphocytes from seven patients with chronic active EBV, six with IM, and 40 healthy, EBV-seropositive individuals. All sequences were compared with the prototype EBV strain B95.8 sequence. All statistical tests were two-sided. Results: Three polymorphic Zp sequences were detected. Among the malignant samples, sequence Zp-P, associated with 84% of type A EBV, was identical to that of EBV strain B95.8, whereas a second sequence (Zp-V3), associated exclusively with type B EBV (P<.001), contained three base substitutions. Among the nonmalignant samples, a distinct polymorphism, Zp-V4, containing the substitutions detected in Zp-V3 and an additional base change, was identified in all samples from chronic active EBV, IM, and healthy individuals, but in none of the malignant samples (P<.001). Zp-V4 was independent of the EBV type. Conclusions: Polymorphisms in the regulatory sequences of BZLF1 are differentially distributed among malignant and nonmalignant cells and may identify EBV subtypes with various lytic activities, including those not associated with malignancies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. H. M. Tong, K. W. Lo, F. W. L. Au, D. P. Huang, and K.-F. To Re: Discrete Alterations in the BZLF1 Promoter in Tumor and Non-Tumor-Associated Epstein-Barr Virus J Natl Cancer Inst, July 2, 2003; 95(13): 1008 - 1009. [Full Text] [PDF]
|
|
|
|
|
|
M. I. Gutierrez, S. E. Straus, M. M. Ibrahim, J. K. Dale, and K. Bhatia RESPONSE: Re: Discrete Alterations in the BZLF1 Promoter in Tumor and Non-Tumor-Associated Epstein-Barr Virus J Natl Cancer Inst, July 2, 2003; 95(13): 1009 - 1009. [Full Text] [PDF]
|
|
|
|
|
|
I. G. Miller Jr. and A. El-Guindy Regulation of Epstein-Barr Virus Lytic Cycle Activation in Malignant and Nonmalignant Disease J Natl Cancer Inst, December 4, 2002; 94(23): 1733 - 1735. [Full Text] [PDF]
|
|